89bio (ETNB) Projected to Post Earnings on Thursday

89bio (NASDAQ:ETNB - Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Thursday, May 1st. Analysts expect 89bio to post earnings of ($0.50) per share for the quarter.

89bio (NASDAQ:ETNB - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.01. During the same quarter last year, the firm posted ($0.54) EPS. On average, analysts expect 89bio to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

89bio Trading Down 1.6 %

ETNB traded down $0.14 during midday trading on Tuesday, reaching $8.47. 389,500 shares of the company were exchanged, compared to its average volume of 1,339,309. The stock has a market capitalization of $1.24 billion, a P/E ratio of -2.92 and a beta of 1.23. 89bio has a one year low of $4.16 and a one year high of $11.84. The company has a debt-to-equity ratio of 0.09, a quick ratio of 11.66 and a current ratio of 11.66. The stock's 50-day simple moving average is $7.37 and its 200 day simple moving average is $8.17.

Insider Buying and Selling at 89bio

In related news, insider Quoc Le-Nguyen sold 15,329 shares of the business's stock in a transaction dated Tuesday, April 15th. The stock was sold at an average price of $5.95, for a total value of $91,207.55. Following the completion of the sale, the insider now directly owns 328,323 shares of the company's stock, valued at $1,953,521.85. The trade was a 4.46 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 2.80% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Citigroup started coverage on shares of 89bio in a research note on Thursday, March 13th. They issued a "buy" rating and a $25.00 price objective for the company. Wolfe Research initiated coverage on shares of 89bio in a research report on Tuesday, February 4th. They set an "outperform" rating on the stock. UBS Group raised their price target on shares of 89bio from $25.00 to $38.00 and gave the company a "buy" rating in a research note on Friday, January 31st. Cantor Fitzgerald upgraded 89bio to a "strong-buy" rating in a report on Wednesday, April 30th. Finally, The Goldman Sachs Group started coverage on 89bio in a research report on Friday, March 14th. They issued a "neutral" rating and a $11.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, 89bio currently has a consensus rating of "Buy" and a consensus price target of $27.25.

89bio Company Profile

89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.